Go Deep
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 23,659 | 24.2 | 2.96 | 0.25 | 854.35 |
| Sep 2026 | 23,659 | 24.2 | 2.96 | 0.25 | 854.35 |
| Sep 2026 | 23,659 | 24.2 | 2.96 | 0.25 | 854.35 |
| Oct 2026 | 23,779 | 23.1 | 2.82 | 0.25 | 815.25 |
| Oct 2026 | 22,994 | 22.7 | 2.77 | 0.25 | 800.95 |
Alembic Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 21,497,700,000.0 | 18,477,200,000.0 | 18,763,100,000.0 | 17,107,200,000.0 |
| Net Profit | 1,730,700,000.0 | 2,027,000,000.0 | 1,329,700,000.0 | 1,543,800,000.0 |
| EPS | 8.8 | 10.3 | 6.8 | 7.8 |
Alembic Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 72,126,100,000.0 | 65,397,100,000.0 | 61,121,100,000.0 | 54,997,700,000.0 | — |
| Net Profit | 6,747,700,000.0 | 5,834,200,000.0 | 6,158,200,000.0 | 3,419,900,000.0 | — |
| EPS | 34.3 | 29.7 | 31.3 | 17.4 | — |
Alembic Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 87,625,900,000.0 | 77,729,400,000.0 | 64,455,800,000.0 | 61,828,300,000.0 | — |
| Total Liabilities | 30,936,100,000.0 | 25,834,200,000.0 | 16,273,800,000.0 | 18,123,700,000.0 | — |
| Total Equity | 56,748,100,000.0 | 51,909,400,000.0 | 48,182,000,000.0 | 43,704,600,000.0 | — |
Owes vs Owns
Alembic Pharmaceuticals Limited owed ₹0.35 for every ₹1 it owned in Mar 2026, up from ₹0.29 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.35× | 0.33× | 0.25× | 0.29× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Alembic Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 2.2%Receivables 16.7%Inventory 28.7%Fixed assets (tangible) 39.9%Intangible assets 3.3%Other assets 8.9%
How it's funded — Mar 2026
Short-term debt 14.1%Long-term debt 1.4%Payables 9.5%Other liabilities 10.2%Shareholders' equity 64.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 196.4 | 83.5 | 120.2 | 75.5 |
| Receivables | 1,466.3 | 1,399.8 | 1,024.8 | 1,046.4 |
| Inventory | 2,510.6 | 2,288.1 | 1,643.5 | 1,475.3 |
| Fixed assets (tangible) | 3,492.7 | 3,391.9 | 3,071.1 | 2,999.7 |
| Intangible assets | 286.8 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 27.7 | 25.7 | 24.4 | 25.1 |
| Other assets | 782.1 | 583.9 | 561.5 | 560.8 |
| Liabilities & equity | ||||
| Short-term debt | 1,238.9 | 1,195.6 | 430.4 | 635.9 |
| Long-term debt | 121.9 | 0.0 | 62.9 | 69.2 |
| Payables | 835.1 | 879.9 | 735.6 | 679.8 |
| Other liabilities | 897.7 | 508.0 | 398.4 | 427.5 |
| Shareholders' equity | 5,669.0 | 5,189.5 | 4,818.2 | 4,370.5 |
| Net tangible assets | 5,388.0 | 5,190.9 | 4,818.2 | 4,370.5 |
Alembic Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 7,827,300,000.0 | 879,700,000.0 | 8,032,000,000.0 | 7,239,500,000.0 | — |
| Investing Activities | -5,060,600,000.0 | -5,684,100,000.0 | -3,206,100,000.0 | -4,475,900,000.0 | — |
| Financing Activities | -1,637,900,000.0 | 4,437,100,000.0 | -4,378,700,000.0 | -2,619,600,000.0 | — |